Shellee Ogawa, MD
Urology · Saint Louis, MONPI 1659722403
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,189 of the $9,016 with a category attached, or 68.6%. 35 manufacturers reported payments, led by Calyxo, Inc. at 31.4% of the total. 2025 is the largest year on record at $3,649, 5.6 times the $648 reported in 2019.
Across 170 payments — averaging $53.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calyxo, Inc.$3K
- Boston Scientific$2K
- Procept Biorobotics Corporation$893
- Conmed Corporation$300
- Baxter Healthcare$249
- Laborie Medical Technologies Corp.$225
- plus $2K from 29 others
What the payments were for
- Consulting fees$3003%
- Travel & lodging$2,44227%
- Food & beverage$6,18969%
- Education$861%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calyxo, Inc. | 24 | $2,835 |
| Boston Scientific | 42 | $2,400 |
| Procept Biorobotics Corporation | 8 | $893 |
| Conmed Corporation | 1 | $300 |
| Baxter Healthcare | 2 | $249 |
| Laborie Medical Technologies Corp. | 4 | $225 |
| AbbVie | 12 | $205 |
| Axonics, Inc. | 5 | $178 |
| Ferring Pharmaceuticals Inc. | 7 | $173 |
| Olympus America Inc. | 3 | $145 |
| Sumitomo Pharma America, Inc. | 6 | $123 |
| SRS Medical Systems, Inc. | 2 | $107 |
| Endo Pharmaceuticals Inc. | 6 | $100 |
| Janssen Scientific Affairs, LLC | 1 | $99 |
| Convatec Inc. | 4 | $95 |
| Johnson & Johnson | 4 | $95 |
| Endo USA, Inc. | 4 | $91 |
| Astellas Pharma US Inc | 3 | $84 |
| Merck | 4 | $74 |
| Dendreon Pharmaceuticals LLC | 2 | $62 |
| Myriad Genetic Laboratories, Inc. | 3 | $59 |
| C. R. Bard, Inc. & Subsidiaries | 3 | $58 |
| Teleflex LLC | 3 | $49 |
| BD | 2 | $44 |
| Novo Nordisk | 2 | $36 |
| AstraZeneca | 1 | $35 |
| Progenics Pharmaceuticals, Inc. | 2 | $35 |
| Tolmar, Inc. | 2 | $32 |
| Azurity Pharmaceuticals, Inc. | 2 | $30 |
| Hologic Sales And Service, LLC | 1 | $20 |
| ABC Home Medical Supply, Inc. | 1 | $20 |
| Vertex | 1 | $18 |
| Palette Life Sciences, Inc. | 1 | $16 |
| Urogen Pharma, Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,016 in reported general payments places this provider in the 80th percentile of 250 urology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 74 | $41,815 |
| GemtesaVibegron | 36 | $28,127 |
| Estradiol | 25 | $2,066 |
| Bethanechol Chloride | 14 | $1,542 |
| Solifenacin Succinate | 13 | $976 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 71 | $848 |
| Tamsulosin Hcl | 102 | $440 |
| Finasteride | 62 | $374 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 69 | $293 |
| Oxybutynin Chloride | 50 | $286 |
| Cefdinir | 40 | $262 |
| Oxybutynin Chloride ErOxybutynin Chloride | 11 | $262 |
| Ciprofloxacin Hcl | 38 | $188 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 17 | $135 |
| Sodium Chloride0.9 % Sodium Chloride | 22 | $79 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $84 | $41,81574 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $123 | $28,12736 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 250 urology providers in Missouri.
Other urology in Saint Louis
- Travis BullockSaint Louis$201K
- Michael JohnsonSaint Louis$160K
- Gurdarshan SandhuSaint Louis$101K
- Gregory McLennanSaint Louis$89K
- Gerald AndrioleSaint Louis$64K
- Charles JonesSaint Louis$55K
- Meredith MetcalfSaint Louis$26K
- Maung Htein ThuSaint Louis$22K
- Alexander ChowSaint Louis$20K
- Jonathan WeeseSaint Louis$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.